A phase I/II open-label, dose-escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide (Revlimid) with topotecan in subjects with advanced ovarian and primary peritoneal carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 19 Dec 2006
At a glance
- Drugs Lenalidomide; Topotecan
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2005 New trial record.